Clinical trials: BCC - Basal Cell Carcinoma
Basal Cell Carcinoma
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Part I is designed as a study of P-MNA application in healthy human volunteers. The goal of Part I is to determine several factors possibly affecting the rate and extent of microneedle array dissolution, such as anatomic…
- Trial name
- NCT04928222
- Testing
- Doxorubicin-containing MNA
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- SkinJect, Inc.
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC).
- Trial name
- NCT03889912
- Testing
- Cemiplimab
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 97 people
- Sponsor
- Regeneron Pharmaceuticals
Carcinoma, Basal Cell (BCC)
Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
This is a Phase 1, open-label, single-arm, multicenter study to assess the safety and tolerability of BSCT (anti-nf-P2X7) 10% Ointment in subjects with BCC.
- Trial name
- NCT02587819
- Testing
- Treatment with BSCT
- Volunteers
- 21 people
- Sponsor
- Biosceptre
Melanoma and Other Malignant Neoplasms of Skin, Basal Cell Carcinoma of Skin
TruScore Standalone Clinical Study
The goal of this clinical trial is to evaluate if the TruScore device can accurately diagnose suspicious skin lesions in patients aged 22 years and older.
- Conditions
- Melanoma and Other Malignant Neoplasms of Skin, Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma of the Skin
- Trial name
- Standalone (NCT06793423)
- Testing
- Skin lesion diagnostic device evaluation
- Where
- 6 sites in United States
- Volunteers
- 464 people
- Sponsor
- VeriSkin, Inc.
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03886181
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Head and Neck Cancer, Oral Complications
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00017511
- Testing
- cevimeline hydrochloride
- Where
- 71 sites in United States
- Sponsor
- Daiichi Sankyo
Basal Cell Carcinoma, Squamous Cell Carcinoma of the Skin
CivaDerm(TM) Surface Therapy Pilot Study
This is a pilot study to determine the usefulness of new brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit basal cell and squamous cell carcinoma…
- Trial name
- NCT04480645
- Testing
- CivaDerm
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- CivaTech Oncology
Skin Cancer, Cutaneous Tumor
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors
- Conditions
- Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis
- Trial name
- NCT04068155
- Testing
- DaRT- Diffusing Alpha-emitters Radiation Therapy
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Alpha Tau Medical LTD.
Basal Cell Carcinoma
Topical Vitamin C for Treatment of Basal Cell Cancer
Randomized coomparative trial of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice a day for 8 weeks vs 5% imiquimod cream in the treatment biopsy proven basal cell carcinomas inotherwise healthy…
- Trial name
- NCT04279535
- Testing
- Topical Ascorbic Acid
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Center for Biomedical Research, Inc.
BCC
Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study
This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC.
- Trial name
- NCT02007317
- Testing
- Oshadi D & Oshadi R
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Oshadi Drug Administration
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.
- Trial name
- NCT02354261
- Testing
- SUBA-Itraconazole
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- HedgePath Pharmaceuticals, Inc.
Merkel Cell Carcinoma, Basal Cell Carcinoma
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
The purpose of this study is to assess the safety and efficacy of RP1 (administered into the tumor) in 90 patients who have received an organ transplant in the past and currently have skin cancer.
- Conditions
- Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
- Trial name
- ARTACUS (NCT04349436)
- Testing
- RP1, intra-tumoral injection, oncolytic virus
- Where
- 24 sites in United States
- Volunteers
- 69 people
- Sponsor
- Replimune, Inc.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma
L19IL2/L19TNF in Skin Cancer Patients
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.
- Conditions
- BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin
- Trial name
- IntriNSiC (NCT05329792)
- Testing
- L19IL2/L19TNF
- Where
- 14 sites in France, Italy and 1 more
- Volunteers
- 70 people
- Sponsor
- Philogen S.p.A.
Superficial Basal Cell Carcinoma
PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities
This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with superficial Basal Cell…
- Trial name
- NCT01325688
- Testing
- PEP005 (ingenol mebutate) Gel, 0.05%, Aluminium disk, OpSite(TM) disk
- Where
- 7 sites in Australia
- Volunteers
- 75 people
- Sponsor
- Peplin
Locally Advanced Basal Cell Carcinoma
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Open label, randomized study in patients with LaBCC not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board.
- Trial name
- NCT07227350
- Testing
- L19IL2, L19TNF, L19IL2/L19TNF
- Where
- 18 sites in United States, Germany and 3 more
- Volunteers
- 180 people
- Sponsor
- Philogen S.p.A.
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
The primary objective is to confirm the safety of treating multiple BCCs once weekly x 3 weeks in individuals with Basal Cell Nevus Syndrome (BCNS).
- Trial name
- NCT03208296
- Testing
- ASN-002
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ascend Biopharmaceuticals Ltd
Basal Cell Nevus Syndrome, Skin Neoplasm
A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
The study evaluates whether ASN-002 is safe and effective in the treatment of nodular basal cell carcinoma (nBCC) in patients aged 18 years or over.
- Conditions
- Basal Cell Nevus Syndrome, Skin Neoplasm, Nodular Basal Cell Carcinoma of Skin
- Trial name
- ASN-002-001 (NCT02550678)
- Testing
- ASN-002, 5-FU
- Where
- 4 sites in Australia
- Volunteers
- 16 people
- Sponsor
- Ascend Biopharmaceuticals Ltd
Advanced Solid Tumor Cancers, Medulloblastoma
An East Asian Study of LDE225
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced…
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT01208831
- Testing
- LDE225
- Where
- 4 sites in Hong Kong, Japan and 1 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Basal Cell Carcinoma
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
This randomized, double-blind, regimen-controlled, phase II, multicenter study will assess the efficacy and safety of two different vismodegib regimens in participants with multiple basal cell carcinoma.
- Trial name
- NCT01815840
- Testing
- Vismodegib
- Where
- 58 sites in United States, Austria and 8 more
- Volunteers
- 229 people
- Sponsor
- Hoffmann-La Roche